• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Risankizumab more effective than ustekinumab for moderate-to-severe psoriasis

byAndrew Cheung, MD MBAandDavid Arsanious
April 21, 2017
in Chronic Disease, Dermatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Risankizumab was associated with a significantly greater improvement in the primary endpoint of ≥90% reduction of the Psoriasis Area and Severity Index (PASI) score than ustekinumab.

2. Risankizumab was also associated with a significantly higher proportion of patients that experienced 100% reduction in the PASI score than ustekinumab.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Plaque psoriasis is a chronic inflammatory skin disease characterized by raised red patches on the skin covered with scale. There is evidence that suggests the proinflammatory cytokine interleukin-23 (IL-23) has a strong influence on the pathogenesis of psoriasis, and so this phase 2 trial was conducted to compare two anti-IL-23 humanized monoclonal antibodies that are used in the management of plaque psoriasis.

Patients in this trial were randomized in a 1:1:1:1 ratio to receive one of three doses of risankizumab or ustekinumab. For the primary end point of ≥90% reduction in the PASI score from baseline, risankizumab was shown to be superior to ustekinumab. For the secondary endpoint of percentage of patients who experienced 100% reduction in PASI score, risankizumab was also shown to be superior to ustekinumab. These findings are compelling as they were derived from a head-to-head comparison of two anti-IL-23 humanized monoclonal antibodies, however as this was a phase 2 trial, the small study population limited the robust assessment of treatment and side effects.

Click to read the study, published in NEJM

Relevant Reading: The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing

RELATED REPORTS

Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention

In-Depth [prospective cohort]: In this 48-week, multicenter, randomized, dose-ranging phase 2 trial, 166 patients were randomized in a 1:1:1:1 ratio to receive one of three doses of risankizumab or ustekinumab. Risankizumab (90 and 180 mg, pooled) was superior to ustekinumab with regard to the primary endpoint at week 12 (77% vs. 40%, p < 0.001). The percentages of patients who experienced 100% reduction in the baseline PASI score were 41% in the 90-mg risankizumab group and 48% in the 180-mg risankizumab group (p < 0.001 for both), versus 18% in the ustekinumab group.

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: psoriasis
Previous Post

Dexamethasone vs placebo for acute sore throat in adults

Next Post

Mixed cardiovascular benefit with PCSK9 inhibitior bococizumab: The SPIRE trial

RelatedReports

Long-term use of apremilast for psoriasis associated with an acceptable safety profile
Chronic Disease

Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults

January 24, 2023
#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis
StudyGraphics

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

April 7, 2022
#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention
StudyGraphics

#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention

January 28, 2022
#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease
StudyGraphics

#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease

December 16, 2021
Next Post
Long-term outcomes for off-pump and on-pump CABG are similar

Mixed cardiovascular benefit with PCSK9 inhibitior bococizumab: The SPIRE trial

Adalimumab aids in control of noninfectious uveitis

Individualized screening for diabetic retinopathy with fundoscopy and HbA1c

Significant healthcare disparities exist between rural and non-rural children

Antidepressant use in pregnancy not linked with autism-spectrum disorder in exposed children

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Faecal haemoglobin concentrations associated with mortality and cause of death in colorectal cancer screening
  • The Scan by 2 Minute Medicine®: Maternity Leave Left Out, Dry January, A Measles Resurgence, Dr. GPT
  • Former professional football players may be at greater risk of chronic disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options